NCT05839275View on ClinicalTrials.gov

The Combination of Radiotherapy，Surufatinib and Sintilimab in High-Risk Localized Soft Tissue Sarcoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

July 31, 2024

Study Completion Date

July 31, 2029

Conditions
High-Risk Localized Soft Tissue Sarcoma
Interventions
DRUG

Surufatinib

In phase Ib: 250mg, 200mg, d1-21，qd; In phase II: recommended phase 2 dose (RP2D), d1-21，qd.

DRUG

Sintilimab

200mg, d1, q3w

RADIATION

Radiotherapy

"BED=50-60Gy (α/β=10); Radiation dose depends on tumor characteristics and organs at risk.~Starts at the begin of the second cycle of systemic therapy (week 4 of the therapy)."

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER